- AU$10.30bn
- AU$9.81bn
- AU$7.50bn
- 77
- 54
- 91
- 84
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 17.87 | ||
| PEG Ratio (f) | 1.59 | ||
| EPS Growth (f) | 12.64% | ||
| Dividend Yield (f) | 4.47% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.38 | ||
| Price to Tang. Book | 5.08 | ||
| Price to Free Cashflow | 31.62 | ||
| Price to Sales | 1.32 | ||
| EV to EBITDA | 9.93 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 22.87% | ||
| Return on Equity | 28.69% | ||
| Operating Margin | 11.38% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 6,763.2 | 6,776.6 | 7,035.1 | 7,108.8 | 7,498.9 | 8,182.66 | 8,508.53 | 2.68% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +3.74 | -26.16 | +52.38 | +11.45 | -32.12 | +46 | +6.53 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Medibank Private Limited is an Australia-based health company. The Company underwrites and distributes private health insurance policies under its two brands, Medibank and ahm. It has two segments. Health Insurance segment offers private health insurance products, including hospital cover and ancillary cover, as stand-alone products or packaged products. Hospital cover provides members with health cover for hospital treatments, whereas ancillary cover provides members with health cover for healthcare services, such as dental, optical and physiotherapy. Medibank Health segment is engaged in a range of activities including contracting with government and corporate customers to provide health management and in-home care services, as well as providing a range of telehealth services in Australia. In addition, the Group distributes travel, life and pet insurance products on behalf of other insurers as part of a broader strategy to retain members and leverage its distribution network.
Directors
- Michael Wilkins NEC (64)
- David Koczkar CEO (48)
- Mark Rogers CFO
- Andrew Wilson CEX
- Kylie Bishop OTH
- Rob Deeming OTH
- John Goodall OTH
- Milosh Milisavljevic OTH
- Mei Ramsay SEC
- Tracey Batten NID (55)
- Anna Bligh NID (61)
- Gerard Dalbosco NID (58)
- David Fagan NID (64)
- Linda Nicholls NID (73)
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- December 1st, 1997
- Public Since
- November 25th, 2014
- No. of Shareholders
- 197,205
- No. of Employees
- 3,242
- Sector
- Insurance
- Industry
- Financials
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 2,754,003,240
- Address
- Level 4, 720 Bourke Street, Docklands, MELBOURNE, 3008
- Web
- https://www.medibank.com.au
- Phone
- +61 300974329
- Auditors
- PricewaterhouseCoopers
Upcoming Events for MPL
Full Year 2024 Medibank Private Ltd Earnings Release
Similar to MPL
AUB
Australian Stock Exchange - SEATS
Challenger
Australian Stock Exchange - SEATS
Clearview Wealth
Australian Stock Exchange - SEATS
Helia
Australian Stock Exchange - SEATS
Insurance Australia
Australian Stock Exchange - SEATS
FAQ
As of Today at 19:14 UTC, shares in Medibank Private are trading at AU$3.74. This share price information is delayed by 15 minutes.
Shares in Medibank Private last closed at AU$3.74 and the price had moved by +6.86% over the past 365 days. In terms of relative price strength the Medibank Private share price has underperformed the ASX All Ordinaries Index by -0.47% over the past year.
The overall consensus recommendation for Medibank Private is Hold. You can view the full broker recommendation list by unlocking its StockReport.
The Medibank Private dividend yield is 4.14% based on the trailing twelve month period.
Last year, Medibank Private paid a total dividend of AU$0.16, and it currently has a trailing dividend yield of 4.14%. We do not have any data on when Medibank Private is to next pay dividends.
We do not have data on when Medibank Private is to next pay dividends. The historic dividend yield on Medibank Private shares is currently 4.14%.
To buy shares in Medibank Private you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of AU$3.74, shares in Medibank Private had a market capitalisation of AU$10.30bn.
Here are the trading details for Medibank Private:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: MPL
Based on an overall assessment of its quality, value and momentum Medibank Private is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Medibank Private is AU$3.90. That is 4.17% above the last closing price of AU$3.74.
Analysts covering Medibank Private currently have a consensus Earnings Per Share (EPS) forecast of AU$0.20 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Medibank Private. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -4.79%.
As of the last closing price of AU$3.74, shares in Medibank Private were trading +4.31% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Medibank Private PE ratio based on its reported earnings over the past 12 months is 17.87. The shares last closed at AU$3.74.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Medibank Private's management team is headed by:
- Michael Wilkins - NEC
- David Koczkar - CEO
- Mark Rogers - CFO
- Andrew Wilson - CEX
- Kylie Bishop - OTH
- Rob Deeming - OTH
- John Goodall - OTH
- Milosh Milisavljevic - OTH
- Mei Ramsay - SEC
- Tracey Batten - NID
- Anna Bligh - NID
- Gerard Dalbosco - NID
- David Fagan - NID
- Linda Nicholls - NID